α-Glukosidase-Hemmer und Thiazolidindione (Glitazone)

详细信息    查看全文

• 作者：Univ.-Prof. Dr. W. A. Scherbaum
• 刊名：Der Diabetologe
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：12
• 期：3
• 页码：178-183
• 全文大小：415 KB
• 刊物主题：Diabetes; General Practice / Family Medicine; Internal Medicine; Angiology; Endocrinology; Metabolic Diseases;
• 出版者：Springer Berlin Heidelberg
• ISSN：1860-9724
• 卷排序：12

文摘

α-Glucosidase inhibitorsThe cardiovascular effects of the α‑glucosidase inhibitors acarbose and miglitol, which are licensed in Germany, cannot be safely judged because of insufficient data and a lack of appropriate outcome trials. A positive cardiovascular effect is as yet uncertain in this class of antidiabetic drugs; they do not appear to be associated with a cardiovascular risk.